News
Clinical study with birch pollen hypoallergen DM-101 continues
First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt. In early 2020, Desentum initiated a clinical study to evaluate the safety and tolerability of DM-101, a hypoallergen designed for...
First-in-Human clinical study with DM-101 paused due to corona virus pandemic
Clinical study initiated in January 2020 with birch pollen hypoallergen DM-101 was suspended in March. The main reason for suspension is that the corona virus epidemic has brought about restrictions in the operations at the study site. In January,...
New scientific paper about hypoallergenic variants of horse allergen Equ c 1
The latest open access paper about our hypoallergen development is available at Nature Scientific Reports. The paper, titled "Development of hypoallergenic variants of the major horse allergen Equ c 1 for immunotherapy by rational structure based...
Desentum will run a clinical trial on its allergy vaccine this winter supported by 4 M€ of new investments
Desentum is about to initiate a first-in-human clinical trial with its birch pollen hypoallergen designed to improve immunotherapeutic treatment of birch pollen allergy. In a funding round arranged by Springvest Oy, the company raised 4 million...
Desentum aims to initiate clinical trials with its birch pollen allergy vaccine this fall
Preparations are currently being finalized for the first clinical study with DM-101 hypoallergen, Desentum’s lead product candidate for the treatment of birch pollen allergy. DM-101 (rBet v 1 dm) is a genetically engineered birch pollen allergen...
Desentum wins a 1.9 M€ EU grant for first-in-human clinical trials
Desentum has been awarded a 1.9 M€ grant from the EIC pilot SME Instrument for a project titled AllergyVAX. The two-and-a-half-year project, starting at the end of 2018, includes early clinical trials of Desentum’s lead product candidate, an...
Syys-lokakuussa on mahdollisuus sijoittaa Desentumiin
Desentumin joukkorahoituskierros käynnistyi 17.9.2019 Desentum on aloittamassa kliiniset tutkimukset ensimmäisellä immunoterapeuttisella tuotteellaan, DM-101:llä, joka on suunnattu koivuallergian hoitoon. Tuotteella pyritään koivuallergian...
Desentum raises EUR 2.3 million to test allergy vaccine
Desentum is progressing towards clinical stage with its first immunotherapeutic product targeting birch pollen allergy. It has raised approx. EUR 2.3 million in a crowd funding campaign arranged by a Finnish investment service company...
Desentum is preparing to start clinical trials with birch pollen allergy vaccine
Desentum is approaching first-in-man clinical trials with its lead product candidate, a modified hypoallergen aimed for an immunotherapeutic treatment of birch pollen allergy. The birch pollen hypoallergen has shown promise in laboratory tests....
Desentum in the media
Here you can find links to articles about Desentum in international media. To see articles in Finnish media, change the language to Finnish from the upper right corner.